Bilypsa Tablet is a medicine used in the treatment of Noncirrhotic Non-Alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease (NAFLD) with comorbidities (like obesity, Type 2 Diabetes Mellitus, Dyslipidemia or Metabolic Syndrome), and high cholesterol in diabetes (diabetic dyslipidemia).
Bilypsa Tablet may be taken with or without food, at the same time each day, to get the most benefit and you should not stop taking it unless your doctor recommends it. It is important to stay on the diet and exercise program recommended by your doctor while taking this medicine. Your lifestyle plays a big part in maintaining a healthy body weight, which will help protect your liver to a great extent.
The most common side effects of this medicine are flatulence, indigestion, abdominal distension, increased body temperature, and weakness. These are usually not severe. Please consult your doctor if the side effects worry you or if they do not go away.
Before taking this medicine, let your doctor know if you have ever had kidney disease, heart or pancreas problems, or if you drink a lot of alcohol. Pregnant or breastfeeding women should also consult their doctor before taking it. Some other medicines you are taking may interfere with it so make sure your doctor knows about all the other medicines you are using. Limit your alcohol intake while taking this medicine because it can degrade your liver health. You may need regular tests such as liver function test, kidney function and blood glucose levels to check that the medicine is working properly.
Noncirrhotic non-alcoholic steatohepatitis (NASH) is liver inflammation and damage caused by excess fat in the liver. Because of the damage, the liver doesn't work as well as it should. Bilypsa Tablet reduces fat deposition thereby improving its overall functioning.
Bilypsa Tablet helps in the management of high cholesterol, as well as blood sugar levels in people with type 2 diabetes. It is mainly used in people whose cholesterol levels are not controlled by statin therapy alone. By controlling high cholesterol levels, Bilypsa Tablet helps reduce the risk of heart diseases.
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if youïre worried about them
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Bilypsa Tablet may be taken with or without food, but it is better to take it at a fixed time.
Bilypsa Tablet contains Saroglitazar, a dual action peroxisome proliferator-activated receptor (PPAR) inhibitor that aids in the management of high cholesterol, especially triglycerides, as well as blood sugar levels in people with type 2 diabetes. It acts by a unique mechanism in which it reduces the synthesis and secretion of triglycerides (a type of lipid or cholesterol in blood). It also improves insulin sensitivity of the body for better utilization of the existing insulin and hence lowers the blood sugar levels.
Alcohol
UNSAFE
It is unsafe to consume alcohol with Bilypsa Tablet.
Pregnancy
CONSULT YOUR DOCTOR
Bilypsa Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Breast feeding
CAUTION
Bilypsa Tablet should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Driving
SAFE
Bilypsa Tablet does not usually affect your ability to drive.
Kidney
CONSULT YOUR DOCTOR
There is limited information available on the use of Bilypsa Tablet in patients with kidney disease. Please consult your doctor.
Liver
CONSULT YOUR DOCTOR
There is limited information available on the use of Bilypsa Tablet in patients with liver disease. Please consult your doctor.
|
SURYA SPECIALITY PHARMA
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |